I agree that this site is using cookies. You can find further informations here.
X
Gluz, O.
36  results:
Search for persons X
?
1

121P Endocrine response assessment in HR+ HER2- early breas..:

Hamann, M. ; Gluz, O. ; Christgen, M....
ESMO Open.  9 (2024)  - p. 103109 , 2024
Link: https://doi.org/10.1016/..
 
?
2

193P Efficacy of sacituzumab govitecan versus treatment of ..:

Gluz, O. ; Xu, B. ; Nanda, R....
ESMO Open.  9 (2024)  - p. 103215 , 2024
Link: https://doi.org/10.1016/..
 
?
3

Significantly longer time to deterioration of quality of li..:

Harbeck, N. ; Fasching, P.A. ; Wuerstlein, R....
Annals of Oncology.  34 (2023)  8 - p. 660-669 , 2023
Link: https://doi.org/10.1016/..
 
?
4

18P A translational project of the WSG-ADAPT-TN trial demon..:

Graeser, M. ; Harbeck, N. ; Gluz, O....
ESMO Open.  8 (2023)  1 - p. 101242 , 2023
Link: https://doi.org/10.1016/..
 
?
5

195P Impact of an interactive eHealth system for patient re..:

Harbeck, N. ; Kates, R.E. ; Schinköthe, T....
ESMO Open.  8 (2023)  1 - p. 101384 , 2023
Link: https://doi.org/10.1016/..
 
?
6

120TiP Premenopausal women with breast cancer optimally tre..:

Fischer, L.A. ; Gluz, O. ; Graeser, M....
ESMO Open.  8 (2023)  1 - p. 101344 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Differential impact of prognostic parameters in hormone rec..:

Christgen, M. ; Harbeck, N. ; Gluz, O....
European Journal of Cancer.  138 (2020)  - p. S1 , 2020
Link: https://doi.org/10.1016/..
 
?
8

ADAPTcycle – adjuvant dynamic marker-adjusted personalized ..:

Harbeck, N. ; Gluz, O. ; Christgen, M....
The Breast.  44 (2019)  - p. S133 , 2019
Link: https://doi.org/10.1016/..
 
?
9

Strong impact of MammaPrint and BluePrint on treatment deci..:

WSG-PRIMe investigators in Germany, Austria, Switzerland ; Wuerstlein, R. ; Kates, R....
Breast Cancer Research and Treatment.  175 (2019)  2 - p. 389-399 , 2019
Link: https://doi.org/10.1007/..
 
?
10

Chemotherapy (CT) decision in node-positive (N+), ER+, earl..:

Mamounas, E.P. ; Goldstein, L.J. ; Penault-Llorca, F....
The Breast.  32 (2017)  - p. S98 , 2017
Link: https://doi.org/10.1016/..
 
?
11

Five-year results of the prospective Phase III WSG PlanB tr..:

Gluz, O. ; Nitz, U. ; Christgen, M....
The Breast.  32 (2017)  - p. S93 , 2017
Link: https://doi.org/10.1016/..
 
?
12

Impact of MammaPrint and BluePrint on early breast cancer t..:

Wuerstlein, R. ; Grischke, E.M. ; Gluz, O....
The Breast.  32 (2017)  - p. S107 , 2017
Link: https://doi.org/10.1016/..
 
?
13

Prädiktive Gensignaturen: Wie valide sind sie?:

Harbeck, N. ; Gluz, O. ; Nitz, U.
Forum.  30 (2015)  2 - p. 134-138 , 2015
Link: https://doi.org/10.1007/..
 
?
14

P231 Luminal subtypes vs. early Ki-67 response and Oncotype..:

Gluz, O. ; Nitz, U. ; Christgen, M....
The Breast.  24 (2015)  - p. S104-S105 , 2015
Link: https://doi.org/10.1016/..
 
?
15

1937 Clinical impact of risk classification by central/loca..:

Gluz, O. ; Nitz, U. ; Kreipe, H.H....
European Journal of Cancer.  51 (2015)  - p. S311 , 2015
Link: https://doi.org/10.1016/..
 
1-15